NAION is a vision-threatening eye condition caused by reduced blood flow to the optic nerve, not linked to arterial inflammation; news centers on FDA warnings about rare, uncertain NAION risks with GLP-1 drugs.
The FDA has required makers of GLP‑1 drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, to add a warning about a rare eye condition called non‑arteritic anterior ischemic optic neuropathy (NAION). The agency has found a small increased risk in trial and real‑world data and is urging patients with sudden, painless vision loss in one eye to seek prompt ophthalmology evaluation.
The FDA has required safety labeling for GLP-1 receptor agonists, warning of a potential link to non-arteritic anterior ischemic optic neuropathy (NAION). While NAION is rare, the agency says cases have been reported and risk factors overlap with patients using GLP-1 therapies. Health providers are urged to monitor for painless vision loss and refer promptly to ophthalmology if suspected.